Investments
8Portfolio Exits
9Partners & Customers
10Service Providers
3About Roche Holding
Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops, and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions which are the pharmaceuticals division and the diagnostics division. The company was founded in 1896 and is based in Basel, Switzerland.
Want to inform investors similar to Roche Holding about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Roche Holding
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Roche Holding in 7 Expert Collections, including Digital Health.
Digital Health
460 items
Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)
Cancer
105 items
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Conference Exhibitors
5,302 items
Diabetes
1,903 items
Medical Devices
4,400 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Health Monitoring & Diagnostics
984 items
At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem
Research containing Roche Holding
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Roche Holding in 7 CB Insights research briefs, most recently on Nov 15, 2022.
Latest Roche Holding News
Feb 2, 2023
02/02/2023 | 01:47am EST Message : By Cecilia Butini Roche Holding AG reported sales growth in 2022, but said it expects a decrease in sales for 2023 due to a drop in the sale of Covid-19 products. The Swiss pharma major posted sales of 63.28 billion Swiss francs ($69.65 billion) for the full year 2022, up from CHF62.80 billion in 2021 and in line with consensus expectations. Net profit declined to CHF13.53 billion from CHF14.94 billion the year prior, missing analysts' expectations of CHF15.09 billion. Core operating profit grew to CHF22.17 billion in the year from CHF21.90 billion the year prior, and core earnings per share also grew to CHF20.30 from CHF19.81 in 2021, the company said. For the year ahead, Roche expects a decrease in sales due to a previously announced CHF5 billion decline in Covid-19 product sales, it said. The expected sales drop is in the low-single digit at constant exchange rates. When excluding the Covid-19 sales decline, the company anticipates "solid underlying sales growth" in both its pharmaceutical and diagnostics division, it said. Write to Cecilia Butini at cecilia.butini@wsj.com (END) Dow Jones Newswires
Roche Holding Investments
8 Investments
Roche Holding has made 8 investments. Their latest investment was in Lead Pharma as part of their Project Finance on November 11, 2020.
Roche Holding Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/17/2020 | Project Finance | Lead Pharma | $11.86M | Yes | 1 | |
4/8/2020 | Project Finance | |||||
12/19/2019 | Partnership | |||||
10/28/2019 | Biz Plan Competition | |||||
10/2/2018 | Partnership |
Date | 11/17/2020 | 4/8/2020 | 12/19/2019 | 10/28/2019 | 10/2/2018 |
|---|---|---|---|---|---|
Round | Project Finance | Project Finance | Partnership | Biz Plan Competition | Partnership |
Company | Lead Pharma | ||||
Amount | $11.86M | ||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 1 |
Roche Holding Portfolio Exits
9 Portfolio Exits
Roche Holding has 9 portfolio exits. Their latest portfolio exit was Ariosa Diagnostics on August 16, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/16/2021 | Acquired - II | 2 | |||
Date | 8/16/2021 | ||||
|---|---|---|---|---|---|
Exit | Acquired - II | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 |
Roche Holding Acquisitions
57 Acquisitions
Roche Holding acquired 57 companies. Their latest acquisition was Good Therapeutics on September 07, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/7/2022 | Series B | $30.19M | Acquired | 14 | ||
9/9/2021 | Acquired | 1 | ||||
3/15/2021 | Acq - Pending | 26 | ||||
10/7/2020 | Series B | |||||
9/21/2020 | Grant |
Date | 9/7/2022 | 9/9/2021 | 3/15/2021 | 10/7/2020 | 9/21/2020 |
|---|---|---|---|---|---|
Investment Stage | Series B | Series B | Grant | ||
Companies | |||||
Valuation | |||||
Total Funding | $30.19M | ||||
Note | Acquired | Acquired | Acq - Pending | ||
Sources | 14 | 1 | 26 |
Roche Holding Partners & Customers
10 Partners and customers
Roche Holding has 10 strategic partners and customers. Roche Holding recently partnered with Sysnav Healthcare on January 1, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
1/25/2023 | Partner | Sysnav Healthcare | VERNON , France , Jan. 25 , 2023 / PRNewswire / -- Sysnav and Roche enter a partnership to facilitate development of industry standard outcome measurements in diseases associated with movement impairments , as well as designing the next generation of wearable technology based on Sysnav 's unique technology . | 5 | |
1/18/2023 | Licensor | Switzerland | AC Immune SA has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech , a member of the Roche Group , Eli Lilly and Company , and others , resulting in substantial non-dilutive funding to advance its proprietary programs and > $ 3 billion in potential milestone payments . | 2 | |
1/18/2023 | Partner | Hong Kong | HKSTP and Roche join hands in strategic collaboration Through our infrastructure , services , expertise and network of partnerships , Hong Kong Science and Technology Parks Corporation will help establish innovation and technology as a pillar of growth for Hong Kong , while reinforcing Hong Kong 's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse . | 1 | |
12/16/2022 | Client | ||||
12/15/2022 | Partner |
Date | 1/25/2023 | 1/18/2023 | 1/18/2023 | 12/16/2022 | 12/15/2022 |
|---|---|---|---|---|---|
Type | Partner | Licensor | Partner | Client | Partner |
Business Partner | Sysnav Healthcare | ||||
Country | Switzerland | Hong Kong | |||
News Snippet | VERNON , France , Jan. 25 , 2023 / PRNewswire / -- Sysnav and Roche enter a partnership to facilitate development of industry standard outcome measurements in diseases associated with movement impairments , as well as designing the next generation of wearable technology based on Sysnav 's unique technology . | AC Immune SA has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech , a member of the Roche Group , Eli Lilly and Company , and others , resulting in substantial non-dilutive funding to advance its proprietary programs and > $ 3 billion in potential milestone payments . | HKSTP and Roche join hands in strategic collaboration Through our infrastructure , services , expertise and network of partnerships , Hong Kong Science and Technology Parks Corporation will help establish innovation and technology as a pillar of growth for Hong Kong , while reinforcing Hong Kong 's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse . | ||
Sources | 5 | 2 | 1 |
Roche Holding Service Providers
3 Service Providers
Roche Holding has 3 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - Pending | Commercial Bank | Financial Advisor | |
Service Provider | |||
|---|---|---|---|
Associated Rounds | Acq - Pending | ||
Provider Type | Commercial Bank | ||
Service Type | Financial Advisor |
Partnership data by VentureSource
Roche Holding Team
74 Team Members
Roche Holding has 74 team members, including current Chief Executive Officer, President, German De La.
Name | Work History | Title | Status |
|---|---|---|---|
German De La | Chief Executive Officer, President | Current | |
Name | German De La | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | ||||
Status | Current |
Compare Roche Holding to Competitors
Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.
Torus Biosystems develops a syndromic diagnostic device designed for use in testing DNA for scientific and medical research purposes. Its Torus Synestia System provides seamless, comprehensive, sample-to-insight test results for major infectious diseases in a faster format than conventional methods, helping for better patient care and improved outcomes. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Hemex creates affordable, life-changing medical diagnostics for under-served people everywhere. Its diagnostic platform is designed to reach populations at risk for malaria and sickle cell disease.
Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.
Genalyte transforms the doctor-patient relationship by providing rapid diagnostic testing right in the doctor's office. The company's technology delivers results to physicians in minutes from just a single drop of blood, yielding better outcomes for the patient, empowering doctors to be more effective, and creating a more efficient healthcare system.
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.